首页 > 最新文献

Atherosclerosis plus最新文献

英文 中文
Hypertriglyceridaemic Pancreatitis, Unmet Needs and How to Address: Preliminary Data from a National Project 高甘油三酯血症性胰腺炎,未满足的需求和如何解决:来自国家项目的初步数据
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.020
Atiqah Sapiyan , Bilal Bashir , Aye Aye Thant , Goran Ahmed , Anoushka Kammath , Maryam Ferdousi , Handrean Soran
{"title":"Hypertriglyceridaemic Pancreatitis, Unmet Needs and How to Address: Preliminary Data from a National Project","authors":"Atiqah Sapiyan , Bilal Bashir , Aye Aye Thant , Goran Ahmed , Anoushka Kammath , Maryam Ferdousi , Handrean Soran","doi":"10.1016/j.athplu.2025.10.020","DOIUrl":"10.1016/j.athplu.2025.10.020","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 10-11"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Apolipoprotein B/LDL-C discordance and lipoprotein(a) as predictors of ASCVD risk in genetically confirmed heterozygous familial hypercholesterolemia (HeFH): A Retrospective Cohort Study (2005–2023) 载脂蛋白B/LDL-C不一致和脂蛋白(a)作为遗传确认的杂合家族性高胆固醇血症(HeFH) ASCVD风险的预测因素:一项回顾性队列研究(2005-2023)
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.006
N. Genedy, S.A. Zouwail
{"title":"Apolipoprotein B/LDL-C discordance and lipoprotein(a) as predictors of ASCVD risk in genetically confirmed heterozygous familial hypercholesterolemia (HeFH): A Retrospective Cohort Study (2005–2023)","authors":"N. Genedy, S.A. Zouwail","doi":"10.1016/j.athplu.2025.10.006","DOIUrl":"10.1016/j.athplu.2025.10.006","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 3-4"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond LDL: Uncovering residual cardiovascular risk in familial hypercholesterolemia – the MATCH-FH cohort study 超越LDL:揭示家族性高胆固醇血症的残留心血管风险- MATCH-FH队列研究
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.018
N. Genedy, S.A. Zouwail
{"title":"Beyond LDL: Uncovering residual cardiovascular risk in familial hypercholesterolemia – the MATCH-FH cohort study","authors":"N. Genedy, S.A. Zouwail","doi":"10.1016/j.athplu.2025.10.018","DOIUrl":"10.1016/j.athplu.2025.10.018","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 10"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Familial Chylomicronaemia Syndrome with Lomitapide 罗米他胺治疗家族性乳糜微粒贫血综合征
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.019
N. Lorde, A. Ochoa-Ferraro, S. Wanninayake, L. Robertson, C. Dawson
{"title":"Treatment of Familial Chylomicronaemia Syndrome with Lomitapide","authors":"N. Lorde, A. Ochoa-Ferraro, S. Wanninayake, L. Robertson, C. Dawson","doi":"10.1016/j.athplu.2025.10.019","DOIUrl":"10.1016/j.athplu.2025.10.019","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 10"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testosterone Undecanoate Significantly Reduces LDL-Cholesterol and Triglycerides in Men with Adult-Onset Testosterone Deficiency 十一酸睾酮可显著降低成年睾酮缺乏症患者的ldl -胆固醇和甘油三酯
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.008
Anirudh Bhat , Arjun Ajith Kumar , Farid Saad , Karim Sultan Haider , Ahmad Haider , Sudarshan Ramachandran
{"title":"Testosterone Undecanoate Significantly Reduces LDL-Cholesterol and Triglycerides in Men with Adult-Onset Testosterone Deficiency","authors":"Anirudh Bhat , Arjun Ajith Kumar , Farid Saad , Karim Sultan Haider , Ahmad Haider , Sudarshan Ramachandran","doi":"10.1016/j.athplu.2025.10.008","DOIUrl":"10.1016/j.athplu.2025.10.008","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 5"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a diagnostic score to identify children with Familial Hypercholesterolaemia – The Familial Hypercholesterolemia Pediatric Diagnostic Score (FH-PeDS) 家族性高胆固醇血症儿童诊断评分的发展——家族性高胆固醇血症儿童诊断评分(FH-PeDS)
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.005
J. Kafol , B. Miranda , R. Sikonja , J. Sikonja , A. Wiegman , FH-PeDS Collaborators, S.E. Humphries , M. Bourbon , U. Groselj
{"title":"Development of a diagnostic score to identify children with Familial Hypercholesterolaemia – The Familial Hypercholesterolemia Pediatric Diagnostic Score (FH-PeDS)","authors":"J. Kafol , B. Miranda , R. Sikonja , J. Sikonja , A. Wiegman , FH-PeDS Collaborators, S.E. Humphries , M. Bourbon , U. Groselj","doi":"10.1016/j.athplu.2025.10.005","DOIUrl":"10.1016/j.athplu.2025.10.005","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 3"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chylomicronaemia secondary to GPIHBP1 autoantibodies giving rise to functional LPL deficiency: is this an under-recognised rare explanation for those with an otherwise unexplained secondary hypertriglyceridaemia? 继发于GPIHBP1自身抗体的乳糜小血症导致功能性LPL缺乏症:对于那些其他原因不明的继发性高甘油三酯血症患者,这是一种未被充分认识的罕见解释吗?
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.011
N.W.P. Cantley , S. Tapley , M. Murakami , K. Nakajima , P. Downie
{"title":"Chylomicronaemia secondary to GPIHBP1 autoantibodies giving rise to functional LPL deficiency: is this an under-recognised rare explanation for those with an otherwise unexplained secondary hypertriglyceridaemia?","authors":"N.W.P. Cantley , S. Tapley , M. Murakami , K. Nakajima , P. Downie","doi":"10.1016/j.athplu.2025.10.011","DOIUrl":"10.1016/j.athplu.2025.10.011","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 6"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world safety and effectiveness of lomitapide in homozygous familial hypercholesterolaemia over ten years: Data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) 洛米他啶治疗纯合子家族性高胆固醇血症的实际安全性和有效性:来自洛米他啶观察性全球评估注册(LOWER)的数据
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.014
Jaimini Cegla , Dirk Blom , James Underberg , Christopher P. Cannon , Dominique Larrey , Lukas Makris , Inbar Aviezer , Ruth Louzado , Sandra Löwe , Sallyann O’Brien
{"title":"Real-world safety and effectiveness of lomitapide in homozygous familial hypercholesterolaemia over ten years: Data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","authors":"Jaimini Cegla , Dirk Blom , James Underberg , Christopher P. Cannon , Dominique Larrey , Lukas Makris , Inbar Aviezer , Ruth Louzado , Sandra Löwe , Sallyann O’Brien","doi":"10.1016/j.athplu.2025.10.014","DOIUrl":"10.1016/j.athplu.2025.10.014","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 8"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innate immune cell function in statin-treated patients with severe hypercholesterolemia is comparable to normocholesterolemic individuals: A cross-sectional study 他汀类药物治疗的严重高胆固醇血症患者的先天免疫细胞功能与正常胆固醇血症患者相当:一项横断面研究
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.11.004
Harsh Bahrar , Kim Steward , Liesbeth van Emst , Nils Rother , Jeanine E. Roeters van Lennep , Mihai G. Netea , Siroon Bekkering , Niels P. Riksen

Background and aims

Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease. Innate immune cells, including monocytes and neutrophils, play important roles in the pathophysiology of atherosclerosis. We previously reported that monocytes from patients with severely elevated low-density lipoprotein (LDL) cholesterol (LDL-c > 4.9 mmol/l) have a hyperresponsive phenotype, which persists even after three months statin treatment. This long-term hyperresponsive innate immune phenotype is termed trained immunity (innate immune memory), and is mediated by persistent enrichment of activating histone modifications leading to higher chromatin accessibility. In this study we investigated the monocyte and neutrophil phenotype of patients with severe hypercholesterolemia treated for 12 months with statins, compared to normocholesterolemic controls.

Methods

In a multicentric cross-sectional study, treatment-naïve patients with severe hypercholesterolemia (defined as LDL-cholesterol >4.9 mmol/L) requiring statin treatment were included. Blood was drawn after 12 months of lipid lowering therapy with statins (n = 15) and compared to healthy normocholesterolemic controls (LDL-c<3.5 mmol/l; n = 18).
We assessed monocyte phenotype with flow cytometry, cytokine production capacity of PBMCs, and H3K4me3 expression on the TNFA promotor. In addition, we assessed the neutrophil phenotype and function.

Results

Treatment lowered LDL-c from 5.8 to 2.7 mmol/L. PBMC cytokine production capacity, as well as the expression of H3K4me3 histone mark on the TNFA promotor did not differ from the controls (LDL-c 2.6 mmol/L). Although neutrophil CD11b, CD66b, and CD62L expression was the same, production of several granular proteins was lower in patients.

Conclusions

Previous studies reported hyperresponsive monocytes in treatment-naïve patients with LDL-c > 4.9 mmol/l. We now demonstrate that in an independent cohort of patients with LDL-c > 4.9 who are treated for 12 months with lipid-lowering drugs, the monocyte phenotype and function was similar to that of normocholesterolemic controls. In addition, neutrophils phenotype was similar, while the secretion of several granular proteins was lower in the patients.
背景与目的高胆固醇血症是动脉粥样硬化性心血管疾病的主要危险因素。先天免疫细胞,包括单核细胞和中性粒细胞,在动脉粥样硬化的病理生理中起重要作用。我们之前报道过低密度脂蛋白(LDL)胆固醇严重升高(LDL-c > 4.9 mmol/l)患者的单核细胞具有高反应表型,即使在他汀类药物治疗三个月后仍持续存在。这种长期的高反应性先天免疫表型被称为训练免疫(先天免疫记忆),并通过持续富集激活组蛋白修饰导致更高的染色质可及性来介导。在这项研究中,我们调查了接受他汀类药物治疗12个月的严重高胆固醇血症患者的单核细胞和中性粒细胞表型,并与正常胆固醇血症对照组进行了比较。方法在一项多中心横断研究中,纳入treatment-naïve需要他汀类药物治疗的严重高胆固醇血症(定义为ldl -胆固醇>;4.9 mmol/L)患者。他汀类药物降脂治疗12个月后抽血(n = 15),并与健康的正常胆固醇水平对照(LDL-c<3.5 mmol/l; n = 18)进行比较。我们用流式细胞术评估了单核细胞表型、PBMCs的细胞因子生产能力和TNFA启动子上H3K4me3的表达。此外,我们还评估了中性粒细胞的表型和功能。结果治疗后LDL-c由5.8 mmol/L降至2.7 mmol/L。PBMC细胞因子生产能力以及TNFA启动子上H3K4me3组蛋白标记的表达与对照组(LDL-c 2.6 mmol/L)没有差异。虽然中性粒细胞CD11b、CD66b和CD62L的表达相同,但患者中几种颗粒蛋白的产生较低。结论既往研究报道LDL-c≥4.9 mmol/l treatment-naïve患者存在高反应性单核细胞。我们现在证明,在LDL-c >; 4.9患者的独立队列中,使用降脂药物治疗12个月后,单核细胞表型和功能与正常胆固醇水平对照组相似。此外,患者的中性粒细胞表型相似,而几种颗粒蛋白的分泌量较低。
{"title":"Innate immune cell function in statin-treated patients with severe hypercholesterolemia is comparable to normocholesterolemic individuals: A cross-sectional study","authors":"Harsh Bahrar ,&nbsp;Kim Steward ,&nbsp;Liesbeth van Emst ,&nbsp;Nils Rother ,&nbsp;Jeanine E. Roeters van Lennep ,&nbsp;Mihai G. Netea ,&nbsp;Siroon Bekkering ,&nbsp;Niels P. Riksen","doi":"10.1016/j.athplu.2025.11.004","DOIUrl":"10.1016/j.athplu.2025.11.004","url":null,"abstract":"<div><h3>Background and aims</h3><div>Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease. Innate immune cells, including monocytes and neutrophils, play important roles in the pathophysiology of atherosclerosis. We previously reported that monocytes from patients with severely elevated low-density lipoprotein (LDL) cholesterol (LDL-c &gt; 4.9 mmol/l) have a hyperresponsive phenotype, which persists even after three months statin treatment. This long-term hyperresponsive innate immune phenotype is termed trained immunity (innate immune memory), and is mediated by persistent enrichment of activating histone modifications leading to higher chromatin accessibility. In this study we investigated the monocyte and neutrophil phenotype of patients with severe hypercholesterolemia treated for 12 months with statins, compared to normocholesterolemic controls.</div></div><div><h3>Methods</h3><div>In a multicentric cross-sectional study, treatment-naïve patients with severe hypercholesterolemia (defined as LDL-cholesterol &gt;4.9 mmol/L) requiring statin treatment were included. Blood was drawn after 12 months of lipid lowering therapy with statins (n = 15) and compared to healthy normocholesterolemic controls (LDL-c&lt;3.5 mmol/l; n = 18).</div><div>We assessed monocyte phenotype with flow cytometry, cytokine production capacity of PBMCs, and H3K4me3 expression on the <em>TNFA</em> promotor. In addition, we assessed the neutrophil phenotype and function.</div></div><div><h3>Results</h3><div>Treatment lowered LDL-c from 5.8 to 2.7 mmol/L. PBMC cytokine production capacity, as well as the expression of H3K4me3 histone mark on the <em>TNFA</em> promotor did not differ from the controls (LDL-c 2.6 mmol/L). Although neutrophil CD11b, CD66b, and CD62L expression was the same, production of several granular proteins was lower in patients.</div></div><div><h3>Conclusions</h3><div>Previous studies reported hyperresponsive monocytes in treatment-naïve patients with LDL-c &gt; 4.9 mmol/l. We now demonstrate that in an independent cohort of patients with LDL-c &gt; 4.9 who are treated for 12 months with lipid-lowering drugs, the monocyte phenotype and function was similar to that of normocholesterolemic controls. In addition, neutrophils phenotype was similar, while the secretion of several granular proteins was lower in the patients.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 53-61"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145748238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“Fear of missing out”: Does upfront combination therapy following acute coronary syndrome (ACS) significantly decrease subsequent eligibility for injectable lipid-lowering therapies? “害怕错过”:急性冠脉综合征(ACS)后的前期联合治疗是否会显著降低后续注射降脂治疗的资格?
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 DOI: 10.1016/j.athplu.2025.10.009
J. Fenwick , H. Sinclair , S.A. Tee
{"title":"“Fear of missing out”: Does upfront combination therapy following acute coronary syndrome (ACS) significantly decrease subsequent eligibility for injectable lipid-lowering therapies?","authors":"J. Fenwick ,&nbsp;H. Sinclair ,&nbsp;S.A. Tee","doi":"10.1016/j.athplu.2025.10.009","DOIUrl":"10.1016/j.athplu.2025.10.009","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 5"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Atherosclerosis plus
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1